中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2015年
13期
90-90,92
,共2页
哮喘缓解期%补肺颗粒%应用%可行性
哮喘緩解期%補肺顆粒%應用%可行性
효천완해기%보폐과립%응용%가행성
Asthma in remission stage%Granule bu fei%Application%Feasibility
目的:分析补肺颗粒在哮喘缓解期治疗中应用的效果及可行性。方法:2013年10月-2014年10月收治哮喘缓解期患者60例,随机分为对照组和观察组。对照组采用常规治疗,观察组采用补肺颗粒治疗,观察两组治疗效果及可行性。结果:治疗后观察组中医症候评分和ACT评分均优于对照组(P<0.05)。治疗后观察组FEV1%、PEF%优于对照组,差异具有统计学意义(P<0.05)。观察组急性哮喘发作次数高于对照组,差异具有统计学意义(P<0.05)。结论:哮喘缓解期患者采用补肺颗粒治疗能够有效控制临床症状,减少哮喘发作次数,值得临床推广使用。
目的:分析補肺顆粒在哮喘緩解期治療中應用的效果及可行性。方法:2013年10月-2014年10月收治哮喘緩解期患者60例,隨機分為對照組和觀察組。對照組採用常規治療,觀察組採用補肺顆粒治療,觀察兩組治療效果及可行性。結果:治療後觀察組中醫癥候評分和ACT評分均優于對照組(P<0.05)。治療後觀察組FEV1%、PEF%優于對照組,差異具有統計學意義(P<0.05)。觀察組急性哮喘髮作次數高于對照組,差異具有統計學意義(P<0.05)。結論:哮喘緩解期患者採用補肺顆粒治療能夠有效控製臨床癥狀,減少哮喘髮作次數,值得臨床推廣使用。
목적:분석보폐과립재효천완해기치료중응용적효과급가행성。방법:2013년10월-2014년10월수치효천완해기환자60례,수궤분위대조조화관찰조。대조조채용상규치료,관찰조채용보폐과립치료,관찰량조치료효과급가행성。결과:치료후관찰조중의증후평분화ACT평분균우우대조조(P<0.05)。치료후관찰조FEV1%、PEF%우우대조조,차이구유통계학의의(P<0.05)。관찰조급성효천발작차수고우대조조,차이구유통계학의의(P<0.05)。결론:효천완해기환자채용보폐과립치료능구유효공제림상증상,감소효천발작차수,치득림상추엄사용。
Objective:To analyze the application effect and feasibility of granule bu fei in the treatment of asthma in remission stage.Methods:60 cases of patients with asthma in remission stage from October 2013 to October 2014 were randomly divided into the control group and the observation group.The control group were given conventional treatment,the observation group were treated with granule bu fei.The therapeutic effect and feasibility of the two groups were observed.Results:After treatment,the TCM symptom score and ACT scores of the observation group were better than that of the control group(P<0.05).After treatment,the FEV1% and PEF% of the observation group were better than that of the control group,and the differences were statistically significant(P<0.05).The times of acute asthma attack of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).Conclusion:Granule bu fei in the treatment of patients with asthma in remission stage could control the clinical symptoms effectively and reduce the number of asthma attacks,worth clinical promotion use.